PROVEN RESULTS WITH NUBEQA®
NUBEQA: Now FDA approved without chemotherapy for men with prostate cancer that has spread (metastatic) and responds to ADT*
In a clinical study, NUBEQA was added to ADT in patients with metastatic castration-sensitive prostate cancer (mCSPC). NUBEQA results were compared to results in men taking ADT alone.
Select inclusion criteria:
- 669 men between the ages of 43 and 93 were included in the ARANOTE study, with a median† age of 70
- 77% of men in the study had stage M1b prostate cancer, meaning their cancer had spread to their bones
- 50% (333 men) were still physically able to do things they could before their disease‡
About two-thirds of the patients in the study took NUBEQA + ADT, while the rest took ADT alone.
*ADT refers to a medical or surgical treatment that lowers testosterone.
†Median is the middle value in a set of numbers, not the average.
‡According to the Eastern Cooperative Oncology Group Performance Status (ECOG PS) scale. 47% of patients had an ECOG performance status score of 1, meaning they were restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.
At the time of analysis, 29% (128 out of 446) of men taking NUBEQA + ADT had cancer worsening via scans or were no longer living compared to 42% (94 out of 223) of men taking ADT alone.
§rPFS is measured by the cancer worsening via scans or the participant no longer living.
